| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| C655837-1ml | 1ml | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $440.90 |
| Specifications & Purity | 10mM in DMSO |
|---|---|
| Storage Temp | Store at -80°C |
| Shipped In | Dry ice |
| Product Description | CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy , which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin ( HY-10219 )-resistant signaling and the growth of glioblastomas in vitro and in vivo In Vivo CC214-2 (25 mg/kg, 50 mg/kg; po; once daily for 21 days) results tumor volume reductions in PC3 tumor xenograft model . CC214-2 (30 mg/kg, 100 mg/kg; po; single dose) inhibits both mTORC1 (pS6) and mTORC2 (pAktS473) in vivo for at least 8 and 24 h, respectively . CC214-2 (30 mg/kg; po) reduces M. tuberculosis CFU numbers and prevents mortality in mice with Chronic M. tuberculosis infection . CC214-2 (50 mg/kg; po; once daily for 6 days) significantly reduces the growth of mouse U87EGFRvIII flank xenografts. CC214-2 (100 mg/kg; po; once every 2 days for 6 days) inhibits mTORC1 and mTORC2 signaling in an intracranial glioblastoma model. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: U87EGFRvIII flank xenografts in miceDosage: 50 mg/kg Administration: PO; once daily for 6 days Result: Inhibited tumor growth. Similarly activated autophagy in U87EGFRvIII xenografts. IC50& Target:mTORC1|mTORC2 |
| Canonical SMILES | O=C1N=C2NC=C(C3=CC=C(C(C)(C)O)N=C3)N=C2N(CC4CCOCC4)C1 |
|---|---|
| Molecular Weight | 383.44 |
Enter Lot Number to search for COA:
